Vivus, Inc. is a biopharmaceutical company. It commercializes and develops therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. The Company's drug, Qsymia (phentermine and topiramate extended-release) was approved by the the United States Food and Drug Administration (FDA) for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 or greater (obese), or 27 or greater (overweight) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol (dyslipidemia). It has completed Phase 2 clinical studies for Qsymia for the treatment of sleeps apnea and Qsymia for the treatment of type 2 diabetes. Its drug also includes STENDRA, or avanafil, is an oral PDE5 inhibitor, which the Company has licensed from Mitsubishi Tanabe Pharma Corporation (MTPC).